EMA Authorised: Scenesse (afamelanotide) — Clinuvel Europe Limited

View source ↗

Summary

The EMA authorised Scenesse (afamelanotide) for erythropoietic protoporphyria, with Clinuvel Europe Limited as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria

Drugs mentioned

• SCENESSE (afamelanotide)

Snippet

Status: Authorised. Therapeutic area: Protoporphyria, Erythropoietic. MAH: Clinuvel Europe Limited. Decision date: 18/09/2025